Phospho-CDC25A (Ser76) Antibody

CDC25A's Role in Cellular Processes and Disease

• Cancer: Research has highlighted CDC25A's involvement in BRCA-mediated tumorigenesis, suggesting potential implications for cancer treatment. (PMID: 29416040)
• Antiviral Immune Response: CDC25A negatively regulates the antiviral immune response by inhibiting TBK1 activity. (PMID: 30021902)
• Neurodegeneration: Studies indicate that CDC25A is elevated and activated in neuronal cell death induced by apoptotic stimuli relevant to normal development and Alzheimer's disease (AD). (PMID: 28333146)
• EGFR Signaling: EGFR activation leads to c-Src-mediated phosphorylation of CDC25A at Y59, which interacts with nuclear pyruvate kinase M2 (PKM2). (PMID: 27485204)
• Head and Neck Squamous Cell Carcinoma (HNSCC): Research suggests the significance of LIMD1 and CDC25A in conjunction with HPV as diagnostic and prognostic markers for HNSCC. RBSP3 also serves as a prognostic marker. (PMID: 29672635)
• Lung Cancer: Inhibition of YBX1 suppressed lung cancer growth partially through the CDC25a pathway, and high expression of YBX1/CDC25a predicts a poor prognosis in human lung adenocarcinoma. (PMID: 27384875)
• Neuroprogenitor Differentiation: MCPH1 interacts with and promotes the E3 ligase betaTrCP2 to degrade CDC25A independent of DNA damage. Overexpression of betaTrCP2 or knockdown of CDC25A remedies the high mitotic index and rescues the premature differentiation of Mcph1-deficient neuroprogenitors in vivo. MCPH1 itself is degraded by APC/CCdh1, but not APC/CCdc20, in late mitosis and G1 phase. (PMID: 29150431)
• Skin Cancer: The cytoplasmic relocalization of CDC25A in skin cancers results in CDC25A acquiring an antiapoptotic function. (PMID: 28951130)
• Hepatocellular Carcinoma (HCC): NPAS2 plays a critical role in HCC cell survival and tumor growth, primarily mediated by transcriptional upregulation of CDC25A. (PMID: 28333141)
• G1/S Transition: CyclinD-CDK4/6 complexes act as novel regulators of CDC25A stability during G1 phase, creating a negative feedback loop that controls the G1/S transition. (PMID: 28192398)
• Entry into Mitosis: A positive regulatory loop exists between CDC25A and its CDK-cyclin substrates, contributing to accelerating entry into mitosis through the regulation of CDC25A activity in G2. (PMID: 27580187)
• MicroRNA Regulation: The expression level of CDC25A significantly increased (<0.05) after treatment with miR-675 mimics. (PMID: 27644634)
• Chondrosarcoma: miR-497 modulates the growth of chondrosarcoma cells by targeting CDC25A. (PMID: 27053344)
• Hepatocellular Carcinoma (HCC) Pathogenesis: Research suggests that the cell cycle pathway and the cdc25a gene are crucial in the pathogenesis and progression of hepatocellular carcinoma. (PMID: 26647881)
• Non-small Cell Lung Cancer (NSCLC): Increased CDC25A is associated with invasiveness in Non-small Cell Lung Cancer. (PMID: 25990966)
• CDC25 Inhibition: Nine compounds were identified with Ki values for CDC25A, -B and -C ranging from 0.01 to 4.4 muM. (PMID: 26474275)
• Acute Myeloid Leukemia (AML): CDC25A acts as an early cell cycle transducer of FLT3-ITD oncogenic signaling, making it a promising target to inhibit proliferation and re-induce differentiation of FLT3-ITD acute myeloid leukemia cells. (PMID: 26515730)
• G2/M Checkpoint Activation: STK38-mediated phosphorylation of CDC25A at Ser-76 and subsequent degradation of CDC25A are essential for promoting DNA damage-induced G2/M checkpoint activation. (PMID: 25936524)
• HCC Progression: let-7c suppresses HCC progression, potentially by directly targeting the cell cycle regulator CDC25A and indirectly affecting its downstream target molecules. Therefore, let-7c might be an effective therapeutic target for HCC. (PMID: 25909324)
• Endometrial Cancer: miR-449a may act as a tumor suppressor by targeting CDC25A in endometrial cancer. (PMID: 24993091)
• AML Phenotype: CDC25C appears to be significant for the phenotype of AML cells, at least for a subset of patients. Many of the identified CDC25 inhibitors exhibit cross-reactivity among the three CDC25 isoforms. (PMID: 25397735)
• Retinoblastoma: Expression of CDC25B may be used as a potential prognostic marker in the pathogenesis of retinoblastoma. (PMID: 25326518)
• Human Cytomegalovirus Replication: CDC25a promotes human cytomegalovirus replication, and elevated CDC25a levels after human cytomegalovirus infection are partly due to human cytomegalovirus-mediated repression of miR-21. (PMID: 25378484)
• Cell Cycle Arrest: miR-424(322)/503-dependent posttranscriptional downregulation of CDC25A cooperates with transcriptional repression of the CDC25A promoter and proteasome-mediated degradation to reduce CDC25A expression levels and induce cell cycle arrest. (PMID: 25266660)
• HCC Migration and Invasion: Inhibition of H19 long non-coding RNA (LncRNAH19) and miR-675 expression can promote migration and invasion of hepatocellular carcinoma (HCC) cells via the AKT/GSK-3beta/Cdc25A signaling pathway. (PMID: 24939300)
• Cholangiocyte Cystogenesis: Accelerated cholangiocyte cystogenesis is likely due to overexpression of CDC25A. (PMID: 24211536)
• Tumor Progression: CDC25A dephosphorylates NFAT, resulting in translocation to the nucleus. NFAT, in cooperation with Smad2, promotes tumor progression. (PMID: 24269534)
• G2/M Transition: RSK promotes G2/M transition in mammalian cells by activating phosphorylation of CDC25A and CDC25B. (PMID: 23708659)
• Breast Cancer: Overexpression of CDC25A was associated with a decrease in overall survival rates and disease-free survival in breast cancer patients. CDC25a is a target of HER2 signaling in human breast cancer. (PMID: 23730206)
• Head and Neck Squamous Cell Carcinoma (HNSCC): Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes. (PMID: 23675485)
• Protein Phosphatase Inhibitor Binding: Data indicate that protein phosphatase inhibitor RE142 binds to one of the residues Cys384-Tyr386 of CDC25A, within a pocket adjacent to the catalytic site. (PMID: 23467652)
• FOXM1 Regulation: Research provides insight into how FOXM1 controls the cell cycle through its association with CDC25A. (PMID: 23240008)
• Hsp90 Inhibition: Destabilization of CDC25A through inhibition of Hsp90 was boosted by the phosphorylation of Ser177, which tags CDC25A to proteasomal degradation, adding to the cell-cycle inhibitory effect. (PMID: 22843495)
• Rock2 Regulation: A new role for Rock2 in modulating CDC25A ubiquitination has been revealed, indicating a novel mechanism of CDC25A regulation and a potential function for Rock2 in the development of hepatocellular carcinoma. (PMID: 22705122)
• Widdrol-Induced Cell Cycle Arrest: Widdrol breaks DNA directly in HT29 cells, resulting in checkpoint activation via the Chk2-p53-Cdc25A-p21-MCM4 pathway, ultimately leading to G1-phase cell cycle arrest and apoptosis. (PMID: 22160829)
• Cancer Cell Survival: CDC25A plays a significant physiological role in NF-kappaB activity regulation and may serve as an important survival mechanism for cancer cells. (PMID: 22417828)
• JAK2(V617F) Patients: CDC25A deregulation may be involved in hematopoietic cell expansion in JAK2(V617F) patients, making this protein an attractive potential therapeutic target. (PMID: 22065597)
• Metastasis: CDC25A enhances Foxo1 stability by dephosphorylating Cdk2, and Foxo1 has been shown to directly regulate the transcription of the metastatic factor MMP1. (PMID: 21670150)
• Sarcoma Proliferation: High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/beta-catenin target gene, CDC25A. (PMID: 21575861)
• Cdk1 Activation: Cdc14A phosphatase prevents premature activation of Cdk1 by regulating CDC25A and CDC25B at the entry into mitosis. (PMID: 20956543)
• Human Gliomas: This study demonstrates the expression levels of CDC25s in human gliomas, finding that CDC25A is overexpressed and significantly correlates with Ki-67 expression. (PMID: 20217459)
• Muscle Differentiation: Research reveals an unexpected role of CDC25A down-regulation and the inhibitory phosphorylation of cdk2 T14 and Y15 in cell cycle quiescence during muscle differentiation, implicating miRNAs-322 and -503 in the process. (PMID: 20462953)
• Breast Cancer Diagnosis and Therapy: 263C/T and -51C/G polymorphisms of the CDC25A gene could be candidate markers for earlier diagnosis and targets for breast cancer therapy. (PMID: 20614206)
• TRB3 Regulation: Results suggest that TRB3 is a regulator for adjusting the expression level of CDC25A both in normal and genotoxic conditions. (PMID: 20606298)
• Checkpoint Kinase 1 Interaction: 14-3-3 protein gamma mediates the interaction between Checkpoint kinase 1 and CDC25A. (PMID: 20639859)
• Casein Kinase 1 Regulation: Casein kinase 1 functions as both penultimate and ultimate kinase in regulating CDC25A destruction. (PMID: 20348946)
• NEK11 Regulation: NEK11 controls degradation of CDC25A by directly phosphorylating CDC25A on residues whose phosphorylation is required for beta-TrCP mediated CDC25A polyubiquitylation and degradation. (PMID: 20090422)
• Dub3 Regulation: As a major regulator of CDC25A, Dub3 is an example of a transforming ubiquitin hydrolase that subverts a key component of the cell cycle machinery, promoting oncogenic transformation. (PMID: 20228808)
• Hypoxia and CDC25A Expression: The reduction in CDC25A mRNA and protein was dependent on the cyclin-dependent kinase inhibitor p21 and miR-21, which were upregulated in HCT116 colon cancer cells during hypoxia. (PMID: 19738433)
• Sp1 Regulation: Results demonstrate through RNA interference that Sp1 regulates CDC25A and FAS expression and proliferation in cancer cells. (PMID: 19621387)

HGNC: 1725

OMIM: 116947

KEGG: hsa:993

STRING: 9606.ENSP00000303706

UniGene: Hs.437705